



2010

Determination of the Effect of Dairy Powders on Adherence of *Streptococcus sobrinus* and *Streptococcus salivarius* to Hydroxylapatite and Growth of these Bacteria

Rachel Halpin

Dublin Institute of Technology, rachel.halpin@dit.ie

D.B. Brady

2School of Biomolecular and Biomedical Science, University College Dublin

E.D. O'Riordan

School of Agriculture, Food Science and Veterinary Medicine, University College Dublin

M. O'Sullivan

School of Agriculture, Food Science and Veterinary Medicine, University College Dublin

Follow this and additional works at: <http://arrow.dit.ie/schfsehart>

 Part of the [Food Biotechnology Commons](#), [Food Chemistry Commons](#), [Food Microbiology Commons](#), and the [Food Processing Commons](#)

Recommended Citation

Halpin, R. et al. (2011) Determination of the Effect of Dairy Powders on Adherence of *Streptococcus sobrinus* and *Streptococcus salivarius* to Hydroxylapatite and Growth of these Bacteria, *Journal of Functional Foods*, Volume 3, Issue 4, October 2011, Pages 280-289 DOI:10.1016/j.jff.2011.05.003

This Article is brought to you for free and open access by the School of Food Science and Environmental Health at ARROW@DIT. It has been accepted for inclusion in Articles by an authorized administrator of ARROW@DIT. For more information, please contact yvonne.desmond@dit.ie, arrow.admin@dit.ie, brian.widdis@dit.ie.



1 **Determination of the Effect of Dairy Powders on Adherence of *Streptococcus***
2 ***sobrinus* and *Streptococcus salivarius* to Hydroxylapatite and Growth of these**
3 **Bacteria**

4
5 R.M. Halpin^{1*}, D.B. Brady^{2§}, E.D. O’Riordan¹ and M. O’Sullivan¹

6 ¹School of Agriculture, Food Science and Veterinary Medicine, University College
7 Dublin, Ireland.

8 ²School of Biomolecular and Biomedical Science, University College Dublin, Ireland.

9 [§]Present Address: School of Science, Athlone Institute of Technology, Athlone,
10 Ireland.

11 *Corresponding author: Rachel Halpin, School of Agriculture, Food Science and
12 Veterinary Medicine, University College Dublin, Ireland.

13 Tel:0035317161301

14 E-mail address: rachel.halpin@ucd.ie

15

16

17

18

19

20

21

22

23

24

25

26 **Abstract**

27 Dental caries is a highly prevalent disease caused by colonisation of tooth surfaces by
28 cariogenic bacteria, such as *Streptococcus sobrinus* and *S. salivarius*. Reducing initial
29 adherence of such bacteria to teeth may delay onset of caries. Many foods, such as
30 milk, can inhibit microbial adherence. In this investigation, the effect of untreated
31 (UT) and enzyme-treated (ET) dairy powders on adherence of *S. sobrinus* and *S.*
32 *salivarius* to hydroxylapatite (HA), an analogue of tooth enamel, was examined. UT
33 acid whey protein concentrate (WPC) 80 inhibited streptococcal adherence to
34 phosphate-buffered saline-coated HA (PBS-HA) and saliva-coated HA (S-HA) by
35 >80% at $\geq 31.25 \mu\text{g mL}^{-1}$. UT sweet WPC80, buttermilk powder and cream powder
36 also significantly reduced adherence ($P < 0.05$). Enzyme-treatment of all dairy powders
37 reduced their anti-adhesion activity. However, ET sweet WPC80 significantly
38 inhibited growth of these streptococci ($P < 0.05$) at $\geq 0.6 \text{mg mL}^{-1}$. Therefore, dairy
39 powders may reduce progression of dental caries by their anti-adhesion and /or
40 antibacterial activity.

41

42 **Keywords:** *Streptococcus sobrinus*, *Streptococcus salivarius*, dairy powders,
43 inhibition of adherence, fluorescence, growth inhibition.

44 **Abbreviations:** PBS-HA; Phosphate-buffered saline-coated hydroxylapatite, S-HA;
45 Saliva-coated hydroxylapatite, SWPC80; Sweet whey protein concentrate 80,
46 AWPC80; Acid whey protein concentrate 80, SWPC35; Sweet whey protein
47 concentrate 35, WPI; Whey protein isolate, WP; Whey powder, DW; Demineralised
48 whey, BMP; Buttermilk powder, CP; Cream powder, EA; Egg albumin, PPL; Porcine
49 pancreatic lipase.

50 1. Introduction

51 Dental caries is a bacterial disease characterised by a localised progressive,
52 molecular disintegration of the tooth (Marcotte and Lavoie, 1998). Tooth decay and
53 periodontal disease are among the most common bacterial infections in humans
54 (Loesche, 1986), affecting both children and adults (Aas *et al.*, 2005). The main
55 etiological agents of human dental caries are the mutans streptococci, such as
56 *Streptococcus sobrinus* (Loimaranta *et al.*, 1997), a strongly acidogenic bacterium
57 (Nascimento *et al.*, 2004). Though it is not a member of the mutans streptococci,
58 *Streptococcus salivarius* is also associated with formation of dental caries (Becker *et*
59 *al.*, 2002). *S. salivarius* is one of the earliest colonisers of the oral cavity following
60 birth (Carlsson *et al.*, 1970), and has long been recognised as a ‘potent acid producer’
61 (Shiere *et al.*, 1951). In addition to causing dental caries, microorganisms inhabiting
62 the oral cavity can be introduced into the bloodstream, leading to occurrence of ‘focal
63 oral infections’, including bacteremia, endocarditis and meningitis (Gendron *et al.*,
64 2000, Reif *et al.*, 2009).

65 Adherence to oral mucosa and tooth surfaces is a vital step for bacterial
66 colonisation of the oral cavity, as adherence provides resistance to salivary flow
67 (Marcotte and Lavoie, 1998). In the 1970’s Liljemark and co-workers proposed that
68 the initial colonisation of the tooth surface was of utmost importance when attempting
69 to prevent or control formation of dental plaque (Liljemark *et al.*, 1978). In recent
70 years, many foods and beverages such as water-soluble protein-fraction (WSPF) of
71 hen egg yolk (Gaines *et al.*, 2003), cranberry constituents (Yamanaka *et al.*, 2004),
72 barley coffee (Papetti *et al.*, 2007) and herbal extracts (Limsong *et al.*, 2004, Chen *et*
73 *al.*, 2005) have been found to reduce adherence of caries-causing bacteria to tooth
74 surfaces. Human milk represents a classic example of how dietary constituents are

75 capable of reducing bacterial adherence (Ofek *et al.*, 2003). It is not unreasonable to
76 speculate that the equivalent components of bovine milk and milk-derived products,
77 such as whey, may also possess adherence inhibitory properties.

78 Addition of rennin or acid to milk causes the casein proteins to coagulate,
79 while the remaining liquid phase is referred to as whey (Zadow, 1994). The main
80 constituents of whey include protein, lactose, vitamins, minerals and traces of milkfat
81 (Anonymous, 2003). Whey proteins are recognised as having both nutritional and
82 functional properties (Smithers, 2008), but some biologically active peptides
83 harboured within these proteins are latent until they are liberated by the action of
84 hydrolytic enzymes (Sinha *et al.*, 2007). Peptides exhibiting antimicrobial properties
85 have been isolated from whey proteins such as β -lactoglobulin, α -lactalbumin and
86 lactoferrin following proteolysis (Lopez-Exposito and Recio, 2006).

87 The milkfat component of whey may also possess antimicrobial activity.
88 Bovine milkfat contains a broad range of fatty acids varying in chain length and
89 degree of saturation (Jensen and Newburg, 1995). In the 1970's, researchers reported
90 that the antimicrobial action observed for milkfat was dependent on the release of free
91 fatty acids and monoglycerides by the hydrolytic action of lipases (Sun *et al.*, 2002).
92 Generally, Gram positive microorganisms (such as streptococci) are lipid sensitive
93 whereas Gram negatives are not (Kabara *et al.*, 1972), but some exceptions to this
94 trend exist (Sprong, 2002).

95 Considering these points, it is evident that both the protein and milkfat
96 constituents of whey may have the potential to inhibit cariogenic bacteria, particularly
97 following enzyme treatment. Further to this, it has been reported that some bioactive
98 peptides derived from dairy proteins can possess multi-functional properties (Haque

99 and Chand, 2008). Thus, in addition to antibacterial peptides, hydrolysis of whey
100 proteins may lead to production of peptides possessing anti-adhesion activity.

101 Research carried out in this laboratory (Halpin *et al.*, 2008) has shown that a
102 range of untreated dairy powders reduced adherence of the cariogenic bacterium *S.*
103 *mutans* to hydroxylapatite, a calcium-phosphate analogue of human tooth enamel
104 (Gibbons *et al.*, 1976, Clark and Gibbons, 1977). Further to this, more recent research
105 carried out by this group has shown that dairy powders pre- and post-hydrolysis can
106 inhibit adhesion of *S. mutans* to HA, and that enzyme treated SWPC80 inhibits
107 growth of this microorganism (Halpin *et al.*, 2011). The aims of the present study
108 were firstly to assess the effects of various untreated and enzyme-treated dairy
109 products on the adherence of *S. sobrinus* and *S. salivarius* to hydroxylapatite.
110 Adherence was examined in the presence and absence of saliva. In addition, the effect
111 of enzyme-treated sweet whey protein concentrate on the growth of these cariogenic
112 streptococci was examined.

113 **2. Materials and Methods**

114 **2.1 Bacterial Isolates and Growth Conditions**

115 *S. sobrinus* (DSM 20742) was obtained from the German Collection of
116 Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). *S. salivarius*
117 (2184 D41287), a clinical isolate, was kindly donated by Professor Martin Cormican,
118 Microbiology Department, National University of Ireland, Galway.

119 Both strains were maintained on Protect™ Bacterial Preserve beads (Technical
120 Service Consultants Ltd, Lancashire, UK) at -80°C. A single bead from the frozen
121 stock culture was used to inoculate a Columbia blood agar plate (CBA: Oxoid,
122 Hampshire, England) and grown aerobically at 37°C for 48 h. A single colony from

123 the blood agar plate was subsequently used to inoculate 20mL of brain heart infusion
124 (BHI) broth (BHI Broth: LabM, Lancashire, UK) and grown under aerobic conditions
125 without shaking at 37°C for 18 h.

126 **2.2 Source and Characterisation of Dairy Powders**

127 Sweet whey protein concentrate (SWPC80), acid WPC 80 (AWPC80), sweet WPC 35
128 (SWPC35), whey protein isolate (WPI), whey powder (WP) and demineralised whey
129 (DW) powders were supplied by Carbery Milk Products (Ballineen, Cork, Ireland).
130 Buttermilk powder (BMP) and cream powder (CP) were supplied by Kerry Group plc
131 (Tralee, Co. Kerry, Ireland). Albumin from chicken egg white (grade V) was supplied
132 by Sigma (Poole, Dorset, UK).

133 Compositional analysis was performed on each dairy product using standard methods.
134 Ash content was analysed according to Malkomesius & Nehring (1951). Fat content
135 was determined according to the method of Röse-Gottlieb (International Dairy
136 Federation, IDF, 1987), protein content was determined by the Kjeldahl method (IDF,
137 1993) and the moisture content was determined by the IDF reference method (IDF,
138 1993).

139 **2.3 Hydrolysate Preparation Conditions**

140 Crude porcine pancreatic lipase (PPL, 100-400 units/ mg protein) (Sigma, Poole,
141 Dorset, England) was used throughout the study. Hydrolysates were prepared in a
142 Fermac 200 fermentor (Electrolab Ltd, Tewkesbury, UK) as follows: a c. 2% (w/v)
143 solution of substrate was prepared by dissolving 20g of dairy powder in 900mL of
144 sterile distilled water and heating at 37° C with stirring for 30 min. Lipase solution (1g
145 of PPL in 100mL of sterile H₂O) was added to the substrate solution to give a final
146 incubation volume of 1 L. The substrates were then incubated for 18 h at 37°C with

147 stirring. The resulting hydrolysates were heated at 60°C for 10 min in order to
148 denature the enzyme(s). Each hydrolysate was then placed on ice and allowed to cool
149 to less than 10°C (approx. 45 min), before being frozen using liquid nitrogen and
150 subsequently lyophilised (Moduloyo, Edwards High Vacuum, Manor Royal, Crawley,
151 Sussex, UK).

152 **2.4 Adhesion Assay**

153 **2.4.1 Preparation of Hydroxylapatite**

154 Hydroxylapatite (HA) beads were supplied by Merck (Darmstadt, Germany). Both
155 buffer-coated and saliva-coated HA were used throughout the study Particle size
156 analysis using a Malvern Mastersizer (Malvern Instruments Ltd., Worcestershire, UK)
157 showed the average diameter ($D [4,3]$) of the HA beads to be approximately 10 μ m.
158 Phosphate-buffered saline coated HA (PBS-HA, PBS: Oxoid, Hampshire, England)
159 was prepared by suspension of 7.5mg mL⁻¹ HA in PBS immediately before use in the
160 adherence assays.

161 Saliva-coated-HA (S-HA) was prepared similarly to the protocol set out by Gibbons
162 and Etherden (1982) as follows: parafilm-stilumated whole saliva was collected in an
163 ice-chilled tube from two healthy donors (1 male, 1 female) at least 1 h after eating,
164 drinking or brushing of teeth. The saliva was heated at 60°C for 30 min to inactivate
165 degenerative enzymes, and subsequently centrifuged at 12,000 \times g for 15 min. The
166 pellet was discarded and the supernatant (i.e. clarified whole saliva) was used to
167 prepare a 7.5mg mL⁻¹ dispersion of HA. Aliquots (150 μ L) of this dispersion were
168 dispensed into the wells of a 96-well V-bottomed plate (Sarstedt, Newton, North
169 Carolina, USA), and incubated at 30°C for 1 h with gentle agitation (4.5 \times g).
170 Following this, the microtitre plate was centrifuged at 805 \times g for 2 min, the
171 supernatants discarded and the S-HA pellets washed twice with sterile pre-warmed

172 PBS to remove excess saliva. The S-HA pellets were subsequently resuspended in
173 sterile PBS for use in the adherence assay.

174 **2.4.2 Preparation of Syto® 13 dye**

175 Syto® 13 dye (Molecular Probes, Oregon, USA) was supplied as a 5mM solution in
176 dimethylsulphoxide (DMSO). This concentration was adjusted to 5µM by appropriate
177 dilution in sterile PBS, and was used only on the day of preparation. Standard curves
178 were constructed to show the relationship between relative fluorescent units (RFU)
179 and colony forming units per millilitre (CFU mL⁻¹) for *S. sobrinus* and *S. salivarius*,
180 which had correlation coefficient values (R²) of 0.993 (Figure 1(a)) and 0.989 (Figure
181 1(b)), respectively.

182 **2.4.3 Assay Protocol**

183 Overnight cultures of *S. sobrinus* and *S. salivarius* were subjected to centrifugation at
184 3220 × g (Eppendorf 5810R, Cambridge, UK) for 10 min and each of the pellets were
185 washed once in sterile PBS. Following a second centrifugation step, the bacterial
186 pellets were re-suspended in PBS, and the OD_{630nm} of the suspensions measured using
187 a Multiskan Ascent spectrophotometer, and adjusted to 0.2 by appropriate dilution
188 with sterile PBS.

189 The adherence assays were carried out as previously described (Halpin *et al.*, 2008,
190 Halpin *et al.*, 2011), using sterile 96-well polystyrene microtitre half-area plates
191 (Nunc, Roskilde, Denmark). Dairy powders were prepared to the required
192 concentration by dispersing the dried powder in PBS. Briefly, 50µL of test material
193 solution at various concentrations was added to the wells, followed by 50µL of PBS-
194 HA or S-HA (7.5 mg mL⁻¹). Bacterial suspension (50µL) was added to the wells, so
195 that the final volume of each well was 150µL. Control wells (no bacteria and/ or no
196 HA) were included in each assay. The plate was incubated at room temperature for 45

197 min, and manually inverted at 5 min intervals to prevent settling of the HA
198 suspension. The plate was subsequently centrifuged at $201 \times g$ to sediment the HA
199 and any adhering bacteria, leaving the non-adhering bacteria in suspension. These
200 non-adhering bacteria were labelled with $10\mu\text{L}$ of $5\mu\text{mol L}^{-1}$ Syto® fluorescent dye.
201 For more information regarding the development and validation of the assay described
202 here, the reader should refer to Halpin *et al.*, 2008.

203 **2.5 Quantification of Bacterial Adherence**

204 Aliquots ($100\mu\text{L}$) of supernatant from the adherence assay containing the non-
205 adhering bacteria were transferred from each well of the half-area plate to the
206 corresponding wells of a black microtitre plate (Costar, Corning Inc., Corning, USA).
207 This plate was allowed to stand at room temperature for 5 min in the dark before
208 reading the fluorescence using a Fluoroskan Ascent plate reader (Thermo Electron
209 Corporation, Finland). The excitation wavelength was 485 nm and the emission
210 intensity was monitored at 538 nm. Three measurements were taken at 5 min
211 intervals, and the average fluorescence calculated. The fluorescence due to the
212 number of bacteria present in the supernatant was determined as a direct readout from
213 the fluorimeter as relative fluorescent units (RFU). The background fluorescence due
214 to non-bacterial components of the assay (i.e. dairy powder and HA) were subtracted.
215 The percentage inhibition of adhesion was calculated as follows:

$$216 \frac{(\textit{Fluorescence due to unbound bacteria})}{(\textit{Fluorescence due tototal input bacteria})} \times 100 \quad (1)$$

217 **2.6 Growth Assays**

218 Growth assays were carried out in sterile 96-well plates (Nunc, Roskilde, Denmark).
219 Overnight cultures of *S. sobrinus* and *S. salivarius* were prepared in BHI broth as
220 described earlier (section 2.1).

221 A working culture containing c. 10^8 colony forming units per millilitre (CFU mL⁻¹)
222 was prepared by adding 1mL of overnight culture to 9mL of sterile BHI broth. Test
223 materials were prepared by dispersing dried dairy powders or hydrolysates in BHI
224 broth to the desired concentration. Aliquots (100μL) of test material were added to the
225 wells of the plate, followed by 100μL of the diluted culture; the final concentrations
226 of test material were 0.6mg mL⁻¹, 1.25mg mL⁻¹, 2.5mg mL⁻¹ and 5mg mL⁻¹. Bacterial
227 growth in the absence of test material (i.e. control growth) was also determined. The
228 plate was then incubated at 37°C for 18 h in a Multiskan Ascent plate reader (Thermo
229 Electron Corporation, Finland). Immediately prior to incubation the plate was shaken
230 for 1 min in order to disperse the suspensions. The optical density (OD) readings at
231 630nm for each well were subsequently recorded at 1 h intervals, with the plate being
232 shaken for 30 s immediately prior to measurement. The initial OD_{630nm} reading,
233 recorded at time 0, of each well was subtracted from all other readings for the
234 corresponding wells over the 18 h incubation time (i.e. to subtract the background
235 OD_{630nm} values). Growth inhibition (%) of *S. sobrinus* and *S. salivarius* due to the
236 presence of dairy powder was calculated using OD_{630nm} values at mid-stationary phase
237 according to the following equation:

238
$$\left[\frac{(OD \text{ Control Growth}) - (OD \text{ Growth in Presence of Dairy Powder})}{(OD \text{ Control Growth})} \right] \times 100 \text{ (2)}$$

239 **2.7 Statistical Analysis**

240 All growth / adherence assays were performed at least three times (n=3). Results were
241 expressed as the mean \pm standard deviation (S.D.). Differences between
242 concentrations within treatments were determined using least significant difference
243 (LSD) test, while differences between treatments were determined using Duncan's
244 test. Both analyses were performed using SAS Version 9.1.3. Data were considered
245 significantly different if $P < 0.05$.

246 **3. Results**

247 Compositional analysis of protein, fat, moisture, ash and lactose content of each dairy
248 powder was determined, and is summarised in Table 1. These were typical of their
249 product types.

250 **3.1 Adherence Assays**

251 Standard curves were constructed to show the relationship between relative
252 fluorescent units (RFU) and colony forming units per millilitre (CFU mL⁻¹) for *S.*
253 *sobrinus* and *S. salivarius*, and are shown in Figure 1 (a) and (b), respectively.

254 **3.1.1 *S. sobrinus***

255 (i) Adherence to Phosphate-Buffered Saline-Coated Hydroxylapatite (PBS-HA)

256 Typically, c. 28% of any given culture of *S. sobrinus* used throughout this study did
257 not adhere to PBS-HA in the absence of test material ('control' in Table 2).

258 Of the UT dairy powders, AWPC80 was the most effective inhibitor of *S. sobrinus*
259 adherence to PBS-HA at 31.25 μ g mL⁻¹ and 62.5 μ g mL⁻¹ ($P < 0.05$). At 62.5 μ g mL⁻¹,
260 UT SWPC80, UT BMP and UT CP showed a significant concentration dependent
261 increase ($P < 0.05$), and at the maximum concentration examined (125 μ g mL⁻¹) UT
262 AWPC80, UT SWPC80, UT BMP and UT CP were found to be equally effective

263 ($P<0.05$). Of the untreated dairy powders, WPI, WP and DW were the poorest
264 inhibitors of *S. sobrinus* adherence to PBS-HA at all concentrations.
265 Following enzyme-treatment, the anti-adhesion activity of all powders was reduced.
266 At $31.25\mu\text{g mL}^{-1}$, all ET dairy powders were only equally as effective as the protein
267 control, egg albumin ($P>0.05$). ET BMP was significantly ($P<0.05$) the most effective
268 inhibitor at $62.5\mu\text{g mL}^{-1}$ and $125\mu\text{g mL}^{-1}$. ET SWPC35, WPI, WP and DW had no
269 inhibitory effect on adherence of *S. sobrinus* to PBS-HA at any concentration, relative
270 to the control ($P>0.05$). The loss in anti-adhesion activity due to enzyme-treatment
271 was most noticeable at the highest concentration ($125\mu\text{g mL}^{-1}$), with all powders
272 (except WP) being significantly ($P<0.05$) less effective when compared to its
273 equivalent untreated form.

274 (ii) Adherence to Saliva-Coated Hydroxylapatite (S-HA)

275 For the adherence assays carried out using *S. sobrinus*, c. 46% of microorganisms in
276 any given culture did not adhere to S-HA under our assay conditions ('control' in
277 Table 3). This value was markedly higher than the control level observed for PBS-
278 HA.

279 The egg albumin protein control inhibited adherence of *S. sobrinus* to S-HA to a
280 greater extent than UT SWPC35, UT WP and UT DW at $31.25\mu\text{g mL}^{-1}$ ($P<0.05$), with
281 UT SWPC35 actually significantly ($P<0.05$) promoting adherence. This was also
282 evident for UT WP and UT DW at $62.5\mu\text{g mL}^{-1}$. At $125\mu\text{g mL}^{-1}$, UT SWPC80, UT
283 AWPC80, UT WPI and UT CP appeared to be the most effective inhibitors of
284 adherence of *S. sobrinus* to S-HA and exhibited similar levels of activity, yet these
285 values were not significantly different from those observed for egg albumin ($P>0.05$).
286 For the enzyme-treated dairy powders, at maximum concentration ($125\mu\text{g mL}^{-1}$), only
287 ET AWPC80 was significantly more effective than egg albumin ($P<0.05$). Also, at

288 this concentration ET WPI, ET DW and ET CP did not reduce adherence of *S.*
289 *sobrinus* to S-HA relative to the control ($P>0.05$). However, at $125\mu\text{g mL}^{-1}$ ET
290 AWPC80, ET SWPC80 and ET BMP significantly inhibited adherence of *S. sobrinus*
291 to S-HA, causing the non-binding population of bacteria to increase to $\geq 80\%$.

292 **3.1.2 *S. salivarius***

293 (i) Adherence to PBS-HA

294 Approximately 41% of any given culture of *S. salivarius* used throughout this study
295 did not adhere to PBS-HA in the absence of test material ('control' in Table 4).

296 With the exception of DW, at $31.25\mu\text{g mL}^{-1}$ all of the UT test materials (including egg
297 albumin) significantly ($P<0.05$) reduced adherence of *S. salivarius* to PBS-HA
298 relative to the control. At $31.25\mu\text{g mL}^{-1}$, UT AWPC80, UT WP and UT BMP
299 exhibited similar levels of inhibition of *S. salivarius* adhesion to PBS-HA (resulting in
300 a non-binding population of 85-90%) and were significantly ($P<0.05$) more potent
301 than the other untreated test materials. UT AWPC80, UT WPI, UT BMP and UT CP
302 were equally as effective at $62.5\mu\text{g mL}^{-1}$ and $125\mu\text{g mL}^{-1}$ ($P>0.05$). However, UT
303 SWPC80 showed an equivalent level of anti-adhesion activity at $125\mu\text{g mL}^{-1}$. Also at
304 this concentration ($125\mu\text{g mL}^{-1}$), all UT powders were more effective than the protein
305 control, egg albumin ($P<0.05$).

306 Subjecting the dairy powders to enzyme treatment reduced their ability to inhibit
307 adherence of *S. salivarius* to PBS-HA. No significant difference was found between
308 any ET test materials ($P>0.05$); furthermore, no ET dairy powder was more effective
309 than the protein control, egg albumin ($P>0.05$).

310 (ii) Adherence to S-HA

311 Due to the large non-binding population of *S. salivarius* to S-HA (c. 66%) it was
312 difficult to establish the efficacy of test materials in reducing adherence of this
313 microorganism to S-HA (Table 5).

314 At 31.25µg mL⁻¹, only UT SWPC80 and UT AWPC80 were found to be more potent
315 inhibitors of *S. salivarius* adhesion to S-HA than egg albumin ($P<0.05$). However, at
316 62.5µg mL⁻¹ and 125µg mL⁻¹, all test materials (including egg albumin) showed equal
317 levels of efficacy ($P>0.05$).

318 Following enzyme-treatment, many of the hydrolysed dairy powders significantly
319 ($P<0.05$) inhibited adherence of *S. salivarius* to S-HA relative to the control, but only
320 ET WPI was found to be more effective than egg albumin ($P<0.05$). At 31.25µg mL⁻¹
321 ¹, ET CP was the least effective inhibitor of *S. salivarius* adherence to S-HA ($P<0.05$).
322 No ET test material was more effective than egg albumin ($P>0.05$) at 62.5µg mL⁻¹
323 and 125µg mL⁻¹. At the maximum concentration examined (125µg mL⁻¹), only ET
324 SWPC35, ET WPI, ET WP and ET DW significantly ($P<0.05$) reduced adherence of
325 *S. salivarius* to S-HA relative to the control ($P<0.05$).

326 **3.2 Growth Assays**

327 ET SWPC80 was found to significantly ($P<0.05$) inhibit growth of *S. sobrinus* and *S.*
328 *salivarius* at all concentrations examined (Figure 2). Previous work in this laboratory
329 demonstrated that ET SWPC80 significantly inhibited growth of the highly cariogenic
330 microorganism *S. mutans* (Halpin *et al.*, 2011), with no other enzyme-treated whey
331 product exhibiting an antibacterial effect against this microorganism (O'Connor *et al.*,
332 2006). Therefore, in the present study only ET SWPC80 was assessed for its
333 antibacterial activity against *S. sobrinus* and *S. salivarius*. The percentage growth
334 inhibition was calculated using formula (1) described earlier (section 2.6). A time

335 point for each *Streptococcus* was chosen, depending on the time taken for the
336 particular microorganism to reach mid-stationary phase. For *S. sobrinus* and *S.*
337 *salivarius* 10 hours and 9 hours incubation were chosen, respectively. Growth was on
338 average inhibited by $85.6\% \pm 5.9$ for *S. sobrinus* at all concentrations. ET SWPC80
339 was less effective at inhibiting growth of *S. salivarius* when compared to inhibition
340 levels observed for *S. sobrinus*. However, growth was nevertheless inhibited by an
341 average of $50.6\% \pm 4.9$ at all concentrations. Growth inhibition was significant at all
342 concentrations for both streptococci relative to control growth ($P < 0.05$).

343 **4. Discussion**

344 The present study has shown that dairy powders can inhibit adherence of *S.*
345 *sobrinus* and *S. salivarius* to HA. The dairy powders were used firstly in their
346 untreated forms, and their anti-adhesion activity was again evaluated following
347 incubation with porcine pancreatic lipase (PPL). Both S-HA and PBS-HA models
348 were employed, to reflect the tooth surface in the presence and absence of saliva,
349 respectively. The S-HA model represents ‘normal’ conditions in the mouth, while the
350 PBS model system reflects conditions where saliva production is impaired (‘dry
351 mouth’ or xerostomia). In cases of xerostomia, an individual can experience severe
352 instances of dental caries. The occurrence of dry mouth is a well recognised clinical
353 problem in adults and children, and essentially occurs when the resting salivary flow
354 rate is less than that of fluid loss from the mouth (Walsh, 2008). This condition can be
355 due to use of certain medications (such as those prescribed for hypertension),
356 radiation treatment of the head and neck, or can be incurred by patients with aplasia of
357 the salivary glands (Sjogren’s syndrome) (Loesche, 1986, Johansson, 2002). In the
358 present study, UT SWPC80, UT AWPC80, UT BMP and UT CP were the most
359 effective inhibitors of adhesion of both *S. sobrinus* and *S. salivarius* to HA in the

360 absence of saliva, and thus may be useful ingredients in the formulation of a dairy-
361 based saliva substitute. In addition, such dairy powders capable of inhibiting
362 adherence of streptococci to oral surfaces may help reduce the occurrence of focal
363 oral infections, as introduction of viridans streptococci resident in the oral cavity into
364 the bloodstream can lead to infections such as bacteremia (Gendron *et al.*, 2000). This
365 occurrence is particularly problematic for patients experiencing neutropenia (Prabhu
366 *et al.*, 2004).

367 The level of 'control' adhesion for both *S. sobrinus* and *S. salivarius* varied
368 greatly between PBS-HA and S-HA model systems. In the presence of saliva, UT
369 SWPC80, UT AWPC80, UT WPI and UT CP were the most effective inhibitors of *S.*
370 *sobrinus* adhesion to S-HA. However, all UT dairy powders (with the exception of
371 SWPC35 and WPI) significantly reduced adherence of *S. salivarius* to S-HA
372 ($P<0.05$). The findings of the present study are difficult to explain, as different levels
373 of anti-adhesion activity were observed for each of the of dairy powders against *S.*
374 *sobrinus* and *S. salivarius*, and the level of inhibition also varied depending on
375 whether PBS-HA or S-HA models were used. A possible reason for the varied levels
376 of efficacy exhibited by the dairy powders against *S. sobrinus* and *S. salivarius* may
377 be due to the different adherence mechanisms of these strains. *S. sobrinus* (a member
378 of the mutans streptococci) possesses a surface adhesin (SpaA) (Tokuda *et al.*, 1990)
379 and genes capable of producing glucosyltransferases (Gilmore *et al.*, 1990), whereas
380 strains of *S. salivarius* (which is not a member of the mutans streptococci) contain
381 proteinaceous components associated with a fibrillar layer outside the cell wall,
382 referred to as the 'fuzzy coat'. This fuzzy coat is believed to mediate attachment of *S.*
383 *salivarius* to host surfaces (Weerkamp *et al.*, 1986). Thus, it is not surprising that the

384 dairy powders (and enzyme-treated versions thereof) do not interact with the different
385 surface proteins of these two streptococci in a similar manner.

386 In general, enzyme-treatment with PPL reduced the anti-adhesion efficacy of
387 the dairy powders in both PBS-HA and S-HA assays, but the degree of reduction was
388 less apparent for the latter. A possible reason for this may be interactions occurring
389 between constituents of the hydrolysates and components of saliva e.g. salivary
390 proteins or peptides. However, this is merely speculative and further research would
391 be required if the exact cause were to be determined. Of the enzyme-treated dairy
392 powders, ET SWPC80, ET AWPC80 and ET BMP were found to be the most
393 effective inhibitors of *S. sobrinus* adherence to S-HA. The majority of ET powders
394 appeared to reduce adherence of *S. salivarius* to S-HA, but this may have been due to
395 a non-specific protein effect, as egg albumin was also observed to reduce *S. salivarius*
396 adherence to S-HA, by about the same amount.

397 While the way in which the dairy powders used in this study are inhibiting
398 adherence of streptococci to HA has not yet been elucidated, protein adsorption
399 experiments performed previously by this research group indicated that proteins
400 present in the dairy powders were associating with the HA beads (Halpin *et al.*, 2011).
401 This is likely to be contributing to the reduction in streptococcal adherence, as the
402 highest level of protein association was observed for UT AWPC80, which was also
403 the most effective inhibitor of streptococcal adherence to PBS-HA. However, it is
404 acknowledged in the context of such complex natural products that this may not be
405 the sole factor involved in inhibiting the adherence of streptococci to HA. In addition,
406 it should be noted that the less effective inhibitors were those which were lowest in
407 fat.

408 Another aspect of the present study was to determine the effect of ET
409 SWPC80 on the growth of *S. sobrinus* and *S. salivarius*. This hydrolysate inhibited
410 growth of these cariogenic bacteria by up to 85% at concentrations as low as 0.6mg
411 mL⁻¹ ($P < 0.05$). The crude PPL used in the present study is known to contain both
412 proteases and lipases (Birner-Grunberger *et al.*, 2003), and it may be that enzyme
413 treatment of the dairy powders used in the present study releases both peptides and
414 free fatty acids that are inactive within the untreated material. Thus, the component(s)
415 of ET SWPC80 contributing to the observed antibacterial activity against *S. sobrinus*
416 and *S. salivarius* may on one hand be antibacterial peptides derived from whey
417 proteins such as β -lactoglobulin, α -lactalbumin or lactoferrin, as these proteins are
418 known to harbour antibacterial peptides that can be released by proteolysis (Lopez-
419 Exposito and Recio, 2006). Alternatively, the antibacterial activity could be due to
420 peptides cleaved from the glycomacropeptide (GMP), which is present in sweet whey
421 products due to the action of chymosin on κ -casein. A study by Malkoski *et al.* (2001)
422 showed that kappacin, a non-glycosylated, phosphorylated form of κ -casein, exhibited
423 significant antibacterial activity against oral pathogens. In addition to the peptide
424 hypothesis, it is possible that free fatty acids present in SWPC80 following enzyme-
425 treatment may have contributed to the antibacterial activity of this hydrolysate.
426 Previous work in this laboratory confirmed the presence of butyric (C₄) and caproic
427 (C₆) acids in SWPC80 after digestion with PPL (Halpin *et al.*, 2011), and it is possible
428 that other fatty acids were present after hydrolysis. However, the exact mechanism of
429 action for the antibacterial activity of ET SWPC80 remains to be elucidated.
430 Nonetheless, the action of PPL on SWPC80 produced an effective antibacterial agent
431 possessing potent antimicrobial activity against caries-causing streptococci.

432 **5. Conclusion**

433 This study has demonstrated that UT dairy powders, in particular sweet and
434 acid WPC80 are effective inhibitors of streptococcal adhesion to buffer-coated and
435 saliva-coated HA. Thus, dairy powders, which are readily available and relatively
436 inexpensive materials, may be suitable dental caries-protective agents for both normal
437 mouth conditions and individuals suffering from xerostomia. The anti-adhesion
438 properties of these dairy powders against streptococci may also potentially reduce
439 occurrence of more serious infections such as bacteremia as a consequence. In
440 addition, it is evident from this study that ET SWPC80 is an effective antimicrobial
441 agent active against *S. sobrinus* and *S. salivarius*. However, future work is necessary
442 in order to establish which specific components of the different products are
443 responsible for the observed inhibition, and also to examine whether the extend the
444 observations of the present study to the oral cavity; thereby and ~~establishing~~ the
445 efficacy of dairy products as therapeutic products *in vivo*.

446 **Literature Cited**

447 Aas, J.A., Paster, B.J., Stokes, L.N., Olsen, I. and Dewhirst, F.E. Defining the normal
448 bacterial flora of the oral cavity (2005) *Journal of Clinical Microbiology* 43 (2005)
449 pp. 5721-5723.

450 Anonymous. Emerging health benefits of whey. *Dairy Council Digest* 74 (2003) pp.
451 31-36.

452 Becker, M.R., Paster, B.J., Leys, E.J., Moeschberger, M.L., Kenyon, S.G., Galvin,
453 J.L., Boches, S.K., Dewhirst, F.E. and Griffen, A.L. Molecular analysis of bacterial
454 species associated with childhood caries. *Journal of Clinical Microbiology* 40 (2002)
455 pp. 1001-1009.

456 Birner-Grunberger, R., Scholze, H., Faber, K. and Hermetter, A. Identification of
457 various lipolytic enzymes in crude porcine pancreatic lipase preparations using
458 covalent fluorescent inhibitors. *Biotechnology and Bioengineering* 85 (2003) pp. 147-
459 154.

460 Brady, D. and Folan, M. The use of milk serum apoproteins in the prophylaxis of
461 bacterial and or viral infections. (2003) Patent Number US2005042299.

462 Carlsson, J., Grahnen, H., Jonsson, G. and Wikner, S. Characterisation of the
463 adherence properties of *Streptococcus salivarius*. *Infection and Immunity* 29 (1970)
464 pp. 459-468.

465 Charney, J. and Tomarelli, R.M. A colorimetric method for the determination of the
466 proteolytic activity of duodenal juice. *Journal of Biological Chemistry* 171 (1947) pp.
467 501-505.

468 Chen, L., Cheng, X., Shi, W., Lu, Q., Go., V.L., Heber, D. and Ma, L. Inhibition of
469 growth of *Streptococcus mutans*, methicillin-resistant *Staphylococcus aureus*, and
470 vancomycin-resistant enterococci by kurarinone, a bioactive flavonoid isolated from
471 *Sophora flavescens*. *Journal of Clinical Microbiology* 43 (2005) pp. 3574-3575.

472 Clark, W.B. and Gibbons, R.J. Influence of salivary components and extracellular
473 polysaccharide synthesis from sucrose on the attachment of *Streptococcus mutans*
474 6715 to hydroxylapatite surfaces. *Infection and Immunity* 18 (1977) pp. 514-523.

475 Gaines, S., James, T.C., Folan, M., Baird, A.W. and O'Farrelly, C. A novel
476 spectrofluorometric microassay for *Streptococcus mutans* adherence to
477 hydroxylapatite. *Journal of Microbiological Methods* 54 (2003) pp. 315-23.

478 Gendron, R., Grenier, D. and Maheu-Robert, L.-F. The oral cavity as a reservoir of
479 bacterial pathogens for focal infections. *Microbes and Infection* 2 (2000) pp. 897-906.

480 Gibbons, R.J., Moreno, E.C. and Spinell, D.M. Model delineating the effects of a
481 salivary pellicle on the adsorption of *Streptococcus miteor* onto hydroxylapatite.
482 *Infection and Immunity* 14 (1976) pp. 1109-112.

483 Gibbons, R. and Etherden, I. Enzymatic modification of bacterial receptors on saliva-
484 treated hydroxyapatite surfaces. *Infection and Immunity* 36 (1982) pp. 52-58.

485 Gilmore, K.S., Russell, R.R.B. and Ferretti, J.J. Analysis of the *Streptococcus downei*
486 *gtfS* gene, which specifies a glucosyltransferase that synthesises soluble glucans.
487 *Infection and Immunity* 58 (1990) pp. 2452-2458.

488 Halpin, R.M., O'Connor, M.M., McMahon, A., Boughton, C., O'Riordan, E.D.,
489 O'Sullivan, M. and Brady, D.B. Inhibition of adhesion of *Streptococcus mutans* to
490 hydroxylapatite by commercial dairy powders and individual milk proteins. *European*
491 *Food Research and Technology* 227 (2008) pp.1499-1506.

492 Halpin, R.M., Brady, D.B., O'Riordan E.D. and O'Sullivan, M. The effect of
493 untreated and enzyme-treated commercial dairy powders on the growth and adhesion

494 of *Streptococcus mutans*. *LWT* (Article in press) (2011) DOI
495 10.1016/j.lwt.2011.01.025

496 Haque, E. and Chand, R. Antihypertensive and antimicrobial bioactive peptides from
497 milk proteins. *European Food Research and Technology* 227 (2008) pp. 7-15.

498 International Dairy Federation. Standard 9C: Determination of fat content of dried
499 milk, dried whey, dried buttermilk and dried butter. (1987)

500 International Dairy Federation. Milk: Determination of the nitrogen content: II. Block
501 digestion method (standard 20B) Brussels: International Dairy Federation. (1993a)

502 International Dairy Federation. Dried Milk and Cream: Determination of water
503 content. Brussels: International Dairy Federation. (1993b)

504 Jensen, R.G. and Newburg, D.S. (1995) Bovine Milk Lipids. In *Handbook of Milk*
505 *Composition* (Ed. Jensen, R.G.), pp. 543-575. Academic Press, San Diego.

506 Johansson, I. Milk and dairy products: possible effects on dental health. *Scandinavian*
507 *Journal of Nutrition* 46 (2002) pp. 119-122.

508 Kabara, J.J., Swieckowski, D.M., Conley, A.J. and Truant, J.P. Fatty acids and
509 derivatives as antimicrobial agents. *Antimicrobial Agents and Chemotherapy* 2 (1972)
510 pp. 23-28.

511 Liljemark, W.F., Schauer, S.V. and Bloomquist, C.G. Compounds which affect the
512 adherence of *Streptococcus sanguis* and *Streptococcus mutans* to hydroxyapatite.
513 *Journal of Dental Research* 57 (1978) pp. 373-379.

514 Limsong, J., Benjavongkulchai, E. and Kuvatanasuchati, J. Inhibitory effect of some
515 herbal extracts on adherence of *Streptococcus mutans*. *Journal of Ethnopharmacology*
516 92 (2004) pp. 281-289.

517 Loesche, W.J. Role of *Streptococcus mutans* in human dental decay. *Microbiological*
518 *Reviews* 50 (1986) pp. 353-380.

519 Loimaranta, V., Tenovou, J., Virtanen, S., Marnila, P., Syvaioja, E.-L., Tupasela, T.
520 and Korhonen, H. Generation of bovine immune colostrum against *Streptococcus*
521 *mutans* and *Streptococcus sobrinus* and its effect on glucose uptake and extracellular
522 polysaccharide formation by mutans streptococci. *Vaccine* 15 (1997) pp. 1261-1268.

523 Lopez-Exposito, I. and Recio, I. Antibacterial activity of peptides and folding variants
524 from milk proteins. *International Dairy Journal* 16 (2006) pp. 1294-1305.

525 Malkomesius, P. E. and Nehring, K. (1951) Chemische Untersuchung von
526 Futtermitteln. In: *Handbuch der Landwirtschaftlichen Versuchs-und*

527 *Untersuchungsmethodik (Band 3)*. (Ed. Herrmann, R.). Naumann Verlag, Berlin,
528 Germany. pp 15-25.

529 Malkoski, M., Dashper, S.G., O'Brien-Simpson, N.M., Talbo, G.H., Macris, M.,
530 Cross, K.J. and Reynolds, E.C. Kappacin, a novel antibacterial peptide from bovine
531 milk. *Antimicrobial Agents and Chemotherapy* 45 (2001) pp. 2309-2315.

532 Marcotte, H. and Lavoie, M.C. Oral microbial ecology and the role of salivary
533 immunoglobulin A. *Microbiology and Molecular Biology Reviews* 62 (1998) pp. 71-
534 109.

535 Nascimento, M.M., Lemos, J.A., Abranches, J., Goncalves, R.B. and Burne, R.A.
536 Adaptive acid tolerance response of *Streptococcus sobrinus*. *Journal of Bacteriology*
537 186 (2004) pp. 6383-6390.

538 O'Connor, M.M., Halpin, R.M., McMahon, A., O'Riordan, E.D., O'Sullivan, M. and
539 Brady, D.B. (2006) Antimicrobial Properties of Dairy Powders. In *Proceedings of the*
540 *36th Annual Research Conference: Food, Nutrition and Consumer Sciences,*
541 *University College Cork, Cork*. pp. 51.

542 Ofek, I., Hasty, D.L. and Sharon, N. Anti-adhesion therapy of bacterial diseases:
543 prospects and problems. *FEMS Immunology and Medical Microbiology* 38 (2003) pp.
544 181-191.

545 Papetti, A., Pruzzo, C., Daglia, M., Grisoli, P., Bacciaglia, A., Repetto, B., Dacarro,
546 C. and Gazzani, G. Effect of barley coffee on the adhesive properties of oral
547 streptococci. *Journal of Agricultural Food Chemistry* 55 (2007) pp. 278-284.

548 Prabhu, R.M., Piper, K.E., Baddour, L.M., Steckelberg, J.M., Wilson, W.R. and Patel,
549 R. Antimicrobial susceptibility patterns among viridans group streptococcal isolates
550 from infective endocarditis patients from 1971 to 1986 and 1994 to 2002.
551 *Antimicrobial Agents and Chemotherapy* 48 (2004) pp. 4463-4465.

552 Reif, S., Roller, J., Rawling, R. and Granato, P.A. Iatrogenic *Streptococcus salivarius*
553 meningitis. *Clinical Microbiology Newsletter* 31 (2009) pp. 6-7.

554 Shiere, F.R., Georgi, C.E. and Ireland, R.L. A study of *Streptococcus salivarius* and
555 its relationship to the dental caries process. *Journal of Dental Research* 30 (1951) pp.
556 116-125.

557 Sinha, R., Radha, C., Prakash, J. and Kaul, P. Whey protein hydrolysate: Functional
558 properties, nutritional quality and utilization in beverage formulation. *Food Chemistry*
559 101 (2007) pp. 1484-1491.

560 Smithers, G.W. Whey and whey proteins- from 'gutter to gold'. *International Dairy*
561 *Journal* 18 (2008) pp. 695-704.

562 Sprong, R.C., Hulstein, M.F.E. and van der Meer, R. Bovine milk fat components
563 inhibit food-borne pathogens. *International Dairy Journal* 12 (2002) pp. 209-215.

564 Sun, C.Q., O'Connor, C.J. and Roberton, A.M. The antimicrobial properties of
565 milkfat after partial hydrolysis by calf pregastric lipase. *Chemico-Biological*
566 *Interactions* 140 (2002) pp.185-198.

567 Tokuda, M., Okahashi, I., Takahashi, M., Nakai, S., Nagoika, M. and Kawagoe, M.
568 Complete nucleotide sequence of the gene for a surface protein antigen for
569 *Streptococcus sobrinus*. *Infection and Immunity* 59 (1990) pp. 3309-3312.

570 Walsh, L.J. Dry mouth: a clinical problem for children and young adults.
571 *International Dentistry South Africa* 9 (2008) pp. 48-58.

572 Weerkamp, A.H., Handley, P.S., Baars, A. and Slot, J.W. Negative staining and
573 immunoelectron microscopy of adhesion-deficient mutants of *Streptococcus*
574 *salivarius* reveal that the adhesive protein antigens are separate classes of cell surface
575 fibril. *Journal of Bacteriology* 165 (1986) pp. 746-755.

576 Yamanaka, A., Kimizuka, R., Kato, T. and Okuda, K. Inhibitory effects of cranberry
577 juice on attachment of oral streptococci and biofilm formation. *Oral Microbiology*
578 *and Immunology* 19 (2004) pp.150-154.

579 Zadow, J. G. (1994). Utilization of milk components: Whey. In: *Modern Dairy*
580 *Technology, Advances in Milk Processing (Volume 1)*, (Ed. Robinson, R.K). Chapman
581 and Hall, London, UK. pp. 313-373.

582

583

584

585

586

587

588

589

590

591

592

593


594

595

596


597 **List of Figures:**

598



599

Formatted: Not Highlight
Formatted



600


Formatted: Not Highlight
Formatted

601


602 **Figure 1:** Standard curves of relative fluorescent units (RFU) Vs colony forming
603 units per millilitre (CFU mL⁻¹) for (a) *S. sobrinus* and (b) *S. salivarius*.

604

605
606
607
608
609
610



611
612



613
614

615 **Figure 2:** Effects of enzyme-treated Sweet WPC80 on the growth of (a) *S. sobrinus*
616 and (b) *S. salivarius*, at 5mg mL⁻¹ (○), 2.5mg mL⁻¹ (□), 1.25mg mL⁻¹ (△), 0.6mg mL⁻¹
617 (●) and control growth in the absence of inhibitor (■). (Data= mean ± standard
618 deviation, n=4).

619
620
621
622
623
624
625
626
627

List of Tables:

Table 1: Compositional analysis of dairy powders used in this study (%).

Dairy Powder	Protein	Fat	Moisture	Ash	Lactose
SWPC80	75.5	8	7.5	3	6
AWPC80	78.2	7.7	6.3	5.9	1.9
SWPC35	34.3	3.4	5.4	6.2	50.7
WPI	86.6	0.1	5.8	2.6	4.9
WP	12.5	1	3.1	9.5	73.9
DW	13	1.8	3.5	0.8	80.9
BMP	30.2	10.8	3.9	6.9	48.2
CP	16.4	49.1	2.1	4.5	27.9

Formatted: Not Highlight
Formatted Table
Formatted

628 Abbreviations: SWPC80= Sweet Whey Protein Concentrate 80, AWPC80= Acid
629 WPC80, SWPC35= Sweet Whey Protein Concentrate 35, WPI= Whey Protein Isolate,
630 WP= Whey Powder and DW= Demineralised whey, BMP= Buttermilk Powder, CP=
631 Cream Powder.

632
633
634
635
636
637
638
639

640 |
641

Table 2: Proportion of *S. sobrinus* (%) not adhering to PBS-HA in the presence of dairy powders at various concentrations.

$\mu\text{g mL}^{-1}$	Untreated			Enzyme-treated			
	Control*	31.25	62.5	125	31.25	62.5	125
	28 \pm 7.1 ^(w)						
SWPC80		33.7 \pm 3.6 ^{a,b,c (w)}	63 \pm 3.1 ^{a (x) ¥}	91 \pm 3.2 ^{a,b (y) ¥}	31 \pm 5.6 ^{a (w,x)}	32.2 \pm 5.9 ^{a,b (w,x)}	40.3 \pm 7.3 ^{a (x)}
AWPC80		90.7 \pm 6.1 ^{d (x) ¥}	99.6 \pm 0.8 ^{b (x) ¥}	100 \pm 4.7 ^{a (x) ¥}	45.4 ^a	44.7 ^{b,c}	39.8 ^{a,b}
SWPC35		34.6 \pm 6.2 ^{a,b (w)}	44.5 \pm 9 ^{c (x)}	66.8 \pm 6.8 ^{c (y) ¥}	35.1 \pm 18.9 ^{a (w)}	27.7 \pm 4.9 ^{b (w)}	34.5 \pm 9.8 ^{a,b,c (w)}
WPI		23.9 \pm 4.2 ^{c (w)}	31.4 \pm 5.6 ^{d (w)}	43 \pm 6.7 ^{d,e (x) ¥}	34.6 \pm 11.9 ^{a (w)}	30.1 \pm 7.2 ^{b (w)}	25.2 \pm 2.8 ^{b,c (w)}
WP		26.9 \pm 4.1 ^{b,c (w)}	32 \pm 5 ^{d (w,x)}	37.5 \pm 4.7 ^{d,e (x)}	24 ^a	23.8 ^b	23.5 ^c
DW		30.4 \pm 3.2 ^{a,b,c (w)}	32.4 \pm 4.7 ^{d (w)}	44.7 \pm 9 ^{d (x) ¥}	29.3 \pm 0.9 ^{a (w)}	24.5 \pm 2 ^{b (w)}	26.4 \pm 3.9 ^{a,b,c (w)}
BMP		73.1 \pm 4.4 ^{e (x) ¥}	85.1 \pm 5 ^{e (y) ¥}	98.4 \pm 3.2 ^{a,b (z) ¥}	45.9 \pm 4.8 ^{a (x)}	56 \pm 3.6 ^{c (x,y)}	65.4 \pm 10.3 ^{d (y,z)}
CP		47.3 \pm 6.3 ^{f (x) ¥}	67.4 \pm 7 ^{a (y) ¥}	90.1 \pm 8.6 ^{b (z) ¥}	31.3 \pm 3.3 ^{a (w,x)}	34 \pm 7.1 ^{a,b (w,x)}	39 \pm 4.4 ^{a,b (x,y)}
Egg Albumin†		38.9 \pm 11.6 ^{a,f (x)}	37.1 \pm 7.6 ^{c,d (x)}	33.8 \pm 5.8 ^{e (w,x)}			

Footnotes: PBS-HA= phosphate-buffered saline-coated hydroxylapatite.

Data presented represent the means (\pm SD) of 3 replicates. Within each column, means bearing different superscripts (a,b,c etc.) are significantly ($P < 0.05$) different. Data within each row bearing different superscripts (x,y,z) show significant ($P < 0.05$) differences between concentrations within (i) untreated and (ii) enzyme-treated dairy powders, with control adherence bearing the superscript 'w'.

¥ denotes significant difference ($P < 0.05$) between the untreated dairy powder and enzyme-treated form thereof at that particular concentration.

*n=52, †= egg albumin is included for the sake of comparison only as a protein control.

Table 3: Proportion of *S. sobrinus* (%) not adhering to S-HA in the presence of dairy powders at various concentrations.

$\mu\text{g mL}^{-1}$	Untreated				Enzyme-Treated		
	Control*	31.25	62.5	125	31.25	62.5	125
	45.8 \pm 10.8 ^(w)						
SWPC80		72.1 \pm 8.7 ^{a(x)}	87 \pm 9.7 ^{a(x)}	87 \pm 10.2 ^{a,b(x)}	82.9 \pm 12 ^{a(x)}	89.3 \pm 8.2 ^{a(x)}	96.8 \pm 5.6 ^{a,b(x)}
AWPC80		83.4 \pm 1.2 ^{b(x)¥}	88.2 \pm 2.3 ^{a(x)}	89.1 \pm 9.7 ^{a(x)}	60.3 \pm 9.1 ^{a,b,c(x)}	81.4 \pm 7.4 ^{a,b(y)}	100 ^{a(z)}
SWPC35		38 \pm 6 ^{c(w)}	47.7 \pm 7.1 ^{b,c(w,x)¥}	62.3 \pm 8.3 ^{c,d(x)}	57.4 \pm 23.7 ^{b,c(w,x)}	68.2 \pm 8.3 ^{b,c,d(x)}	76 \pm 15 ^{b,c,d(x)}
WPI		64.3 \pm 3.1 ^{a,d(x)¥}	78.7 \pm 4.9 ^{a,d(x,y)¥}	89.6 \pm 4.8 ^{a(y)¥}	47.3 \pm 5.8 ^{b,c(w)}	54.6 \pm 6.6 ^{d,e(w)}	58.5 \pm 14 ^{c,d,e(w)}
WP		27.4 \pm 4.3 ^{c(x)¥}	41 \pm 13.3 ^{c(w,x,y)}	53.3 \pm 16.8 ^{d,e(w,y)}	55.4 \pm 10.8 ^{b,c(w,x)}	63.4 \pm 10.6 ^{b,c,d(x,y)}	76.1 \pm 2.8 ^{b,c,d(y)}
DW		36.7 \pm 4.2 ^{c(w)}	41.8 \pm 9.7 ^{c(w)}	44.3 \pm 9.3 ^{e(w)}	37.5 \pm 10.3 ^{c(w)}	39.6 \pm 11 ^{e(w)}	48.4 \pm 11 ^{e(w)}
BMP		52.1 \pm 12.1 ^{e(w)}	61.9 \pm 14.7 ^{b,d(x)}	69.4 \pm 10.4 ^{b,c,d(x)}	62.1 \pm 18.7 ^{a,b(x)}	78.9 \pm 13.1 ^{a,b,c(x)}	80.1 \pm 16.7 ^{a,b,c(x)}
CP		57.1 \pm 6.6 ^{d,e(w)}	62.6 \pm 3.7 ^{b,d(x)}	71.1 \pm 9.2 ^{a,b,c,d(x)}	62.2 \pm 10.8 ^{a,b(x)}	58.1 \pm 20.5 ^{c,d,e(w,x)}	55.8 \pm 22.2 ^{d,e(w,x)}
Egg Albumin†		51.2 \pm 5.5 ^{e(w,x)}	65.5 \pm 12.1 ^{b,d(x,y)}	76.1 \pm 7.4 ^{a,b,c(y)}			

Footnotes: S-HA= saliva-coated hydroxylapatite.

Data presented represent the means (\pm SD) of 3 replicates. Within each column, means bearing different superscripts (a,b,c etc.) are significantly ($P < 0.05$) different. Data within each row bearing different superscripts (x,y,z) show significant ($P < 0.05$) differences between concentrations within (i) untreated and (ii) enzyme-treated dairy powders, with control adherence bearing the superscript 'w'.

¥ denotes significant difference ($P < 0.05$) between the untreated dairy powder and enzyme-treated form thereof at that particular concentration.

*n=53, †= egg albumin is included for the sake of comparison only as a protein control.

Table 4: Proportion of *S. salivarius* (%) not adhering to PBS-HA in the presence of dairy powders at various concentrations.

$\mu\text{g mL}^{-1}$	Untreated			Enzyme-Treated			
	Control*	31.25	62.5	125	31.25	62.5	125
	40.7 \pm 10.6 ^(w)						
SWPC80		61.3 \pm 8.2 ^{a,b (x)}	75 \pm 8 ^{a,b,c (x) ¥}	89.5 \pm 2.8 ^{a,b,c,d (y) ¥}	50.9 \pm 9.8 ^{a,b (w,x)}	53.2 \pm 6.6 ^{a (x)}	56.6 \pm 5.4 ^{a (x)}
AWPC80		90.4 \pm 6.7 ^{c (x) ¥}	98.6 \pm 1.8 ^{d (x) ¥}	97.8 \pm 4.3 ^{a (x) ¥}	40.4 \pm 4.4 ^{a,b (w)}	40.9 \pm 5.7 ^{a,b (w)}	39.7 \pm 8 ^{a,b (w)}
SWPC35		63.2 \pm 9 ^{a,b (x)}	69.3 \pm 6.4 ^{a,b,c (x) ¥}	77.2 \pm 3.6 ^{d (x) ¥}	47.1 \pm 10.7 ^{a,b (w)}	42.2 \pm 8 ^{a,b (w)}	39.4 \pm 5.6 ^{a,b (w)}
WPI		65.4 \pm 16.5 ^{a,b (x)}	84.8 \pm 15.7 ^{a,b,d (y)}	94.2 \pm 5.3 ^{a,b (y) ¥}	26.2 ^b	25.6 ^b	27.2 ^b
WP		86.5 \pm 12.7 ^{c,d (x) ¥}	74.3 \pm 16.8 ^{a,b,c (x)}	84 \pm 15.7 ^{b,c,d (x)}	39.3 \pm 9.8 ^{a,b (w)}	51 \pm 24.5 ^{a,b (w)}	50.1 \pm 21.4 ^{a,b (w)}
DW		51.2 \pm 14.3 ^{b (w)}	67.3 \pm 17.7 ^{b,c (x)}	78.7 \pm 12.8 ^{c,d (x) ¥}	38.4 ^{a,b}	44.1 ^{a,b}	30.5 ^b
BMP		85.6 \pm 9.3 ^{c,d (x) ¥}	89.7 \pm 7.7 ^{a,d (x) ¥}	95.6 \pm 3.1 ^{a,b (x) ¥}	44.8 \pm 11.6 ^{a,b (w)}	41.6 \pm 8.2 ^{a,b (w)}	39.7 \pm 11 ^{a,b (w)}
CP		71.1 \pm 9.3 ^{a,d (x)}	83.3 \pm 11.6 ^{a,b,d (x,y) ¥}	90.8 \pm 7 ^{a,b,c (y,z) ¥}	64.2 \pm 19.1 ^{a (x)}	49.7 \pm 11.8 ^{a,b (w,x,y)}	47 \pm 15.3 ^{a,b (y)}
Egg Albumin†		60.6 \pm 10.1 ^{a,b (x)}	56.7 \pm 16.2 ^{c (x,y)}	41.6 \pm 1.8 ^{e (w,y)}			

Footnotes: PBS-HA= phosphate-buffered saline-coated hydroxylapatite.

Data presented represent the means (\pm SD) of 3 replicates. Within each column, means bearing different superscripts (a,b,c etc.) are significantly ($P < 0.05$) different. Data within each row bearing different superscripts (x,y,z) show significant ($P < 0.05$) differences between concentrations within (i) untreated and (ii) enzyme-treated dairy powders, with control adherence bearing the superscript 'w'.

¥ denotes significant difference ($P < 0.05$) between the untreated dairy powder and enzyme-treated form thereof at that particular concentration.

*n=59, †= egg albumin is included for the sake of comparison only as a protein control.

Table 5: Proportion of *S. salivarius* (%) not adhering to S-HA in the presence of dairy powders at various concentrations.

$\mu\text{g mL}^{-1}$	Untreated				Enzyme-Treated		
	Control*	31.25	62.5	125	31.25	62.5	125
	66.2 ±15.7 ^(w)						
SWPC80		95.7 ±3.4 ^{a(x)}	87.1 ±5.7 ^{a(x)}	90.9 ±6.1 ^{a(x)¥}	91.1 ±3.9 ^{a,b(x)}	83.8 ±6.5 ^{a,b(w,x)}	68.3 ± 8.3 ^{a,b(w,x)}
AWPC80		95.7 ±7.4 ^{a(x)}	93.3 ±5.8 ^{a(x)}	98.7 ±2.2 ^{a(x)¥}	89.7 ±13.6 ^{a,b(x)}	89.2 ±12.7 ^{a,b(x)}	60.8 ±7.7 ^{a,b(w,y)}
SWPC35		69.2 ± 18.1 ^{b(w)}	77.8 ±22.7 ^{a(w)}	79.7 ±18.3 ^{a(w)}	83.8 ±3.9 ^{a,b,c(x)}	91.4 ±9.9 ^{a(x)}	89.5 ±9.6 ^{a(x)}
WPI		65 ± 25 ^{b(w)}	70.5 ±22.8 ^{a(w)}	77 ±19.5 ^{a(w)}	93.6 ±6.5 ^{a(x)}	94.7 ±12.5 ^{a(x)}	96.4 ±5.5 ^{a(x)}
WP		80.7 ±10.5 ^{a,b(w,x)}	86.2 ±1.3 ^{a(x)}	87.7 ±13.8 ^{a(x)}	80.8 ±5.7 ^{a,b,c(w,x)}	83.4 ±8.9 ^{a,b(w,x)}	91.1 ±12.4 ^{a(x,y)}
DW		81.2 ±15.2 ^{a,b(w,x)}	83.8 ±14.2 ^{a(w,x)}	85 ±18.6 ^{a(x)}	84 ± 9.9 ^{a,b,c(w,x)}	86.7 ±7 ^{a,b(x)}	95.2 ±6.7 ^{a(x)}
BMP		87.9 ±7.9 ^{a,b(x)}	84.1 ±15.1 ^{a(x)}	91.3 ±10.2 ^{a(x)}	90.1 ±2.7 ^{a,b(x)}	70.3 ±13.2 ^{a,b(w,x)}	52.2 ±33.6 ^{b(w,y)}
CP		67 ±13.6 ^{b(w,x)}	72.1 ±8.4 ^{a(w,x)}	88.2 ±13.1 ^{a(x)}	62.6 ±38.6 ^{c(w)}	63 ±33.2 ^{b(w)}	69.8 ±49.7 ^{a,b(w)}
Egg Albumin†		66.2 ±12.5 ^{b(w)}	75.8 ±9.2 ^{a(w)}	76.9 ±8.2 ^{a(w)}			

Footnotes: S-HA= saliva-coated hydroxylapatite.

Data presented represent the means (\pm SD) of 3 replicates. Within each column, means bearing different superscripts (a,b,c etc.) are significantly ($P<0.05$) different. Data within each row bearing different superscripts (x,y,z) show significant ($P<0.05$) differences between concentrations within (i) untreated and (ii) enzyme-treated dairy powders, with control adherence bearing the superscript 'w'.

¥ denotes significant difference ($P<0.05$) between the untreated dairy powder and enzyme-treated form thereof at that particular concentration.

*n=57, †= egg albumin is included for the sake of comparison only as a protein control.